Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Published . Updated .
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different story from the obesity-driven surge at Eli Lilly (NYSE:LLY). In
Directly affected
- MRK Merck-2.6% 16d
Named in this report.
- LLY Eli Lilly+12.0% 30d
Named in this report.
- JNJ Johnson & Johnson+0.4% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Johnson & Johnson belongs to, so it often moves with news about it.
- ABBV AbbVie+8.5% 30d
AbbVie is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories-0.7% 30d
Abbott Laboratories is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- PFE Pfizer+6.7% 30d
Pfizer is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- VRTX Vertex Pharmaceuticals+2.6% 30d
Vertex Pharmaceuticals is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- BMY Bristol-Myers Squibb-3.5% 30d
Bristol-Myers Squibb is a peer of Johnson & Johnson in pharmaceutical preparations; rivals often move on the same news.
- REGN Regeneron Pharmaceuticals+10.8% 30d
Regeneron Pharmaceuticals is a peer of Eli Lilly and in pharmaceutical preparations; rivals often move on the same news.
- RPRX Royalty Pharma
Royalty Pharma is a peer of Eli Lilly and in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MRK | +4.32% | -0.31% | base | +4.95% | after close | after close | after close |
| LLY | +1.25% | -0.87% | base | +6.77% | after close | after close | after close |
| JNJ | -1.32% | -1.82% | base | +1.29% | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| ABBVNo price data for this ticker | — | — | — | — | — | — | — |
| ABTNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| VRTXNo price data for this ticker | — | — | — | — | — | — | — |
| BMYNo price data for this ticker | — | — | — | — | — | — | — |
| REGNNo price data for this ticker | — | — | — | — | — | — | — |
| RPRXNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher 24/7 Wall St.
Source: 24/7 Wall St.
This story
| Company | When | Move | Status |
|---|---|---|---|
| JNJ | that day | +1.29% | still updating |
| JNJ | three days earlier | -1.82% | final price |
| JNJ | five days earlier | -1.32% | final price |
| LLY | that day | +6.77% | still updating |
| LLY | three days earlier | -0.87% | final price |
| LLY | five days earlier | +1.25% | final price |
| MRK | that day | +4.95% | still updating |
| MRK | three days earlier | -0.31% | final price |
| MRK | five days earlier | +4.32% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 71 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 90 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 34 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 51 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 45 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought AbbVie (ABBV), worth $50,001 - $100,000 on 31 Jul 2026. That is 90 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 41 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher” scores 12 out of 100. The score uses 1 sources. The price is not final yet.